Lihui Wang

13PUBLICATIONS
19CO-AUTHORS
Molecular medicineMolecular targetsBiologically active moleculesCheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jun 29, 2026
4-Arylindolines Bearing a Pyrido[3,2-d]pyrimidine Scaffold as Dual Inhibitors of the PD-1/PD-L1 Interaction and NAMPT for Targeting Tumor Immunoevasion and Metabolism.

|Feb 04, 2026
Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression.

Shougeng Liu, Yiting Jiang, Yudong Fu

|Nov 28, 2025
Novel Isoidide Subunit-Containing Xanthine Oxidase Inhibitors with Potent Hypouricemic Effects.

Xiaoyi Zeng, Yu Chen, Bing Xu

|Sep 30, 2025
Activation of epigenetic reprogramming via crotonylation overcomes resistance to EGFR-TKI therapy in lung cancer.

Sihong Chen, Mengyan Zhong, Xiaoyuan Wang

|Sep 17, 2025
Discovery of Pyrazole-Containing 4‑Arylindolines as Potent Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.

Wensong Deng, Yuan Yang, Tairen Zhou

|Nov 08, 2024
Loss of CDKN2A Enhances the Efficacy of Immunotherapy in EGFR-Mutant Non-Small Cell Lung Cancer.

Simeng Wang, Jia-Cheng Lai, Yu Li

Pageof 3

Frequent Collaborators

4 joint publications

Mingze Qin

2 joint publications

Yongshan Zhao

2 joint publications

Jingyu Yang

2 joint publications

Simeng Wang